" class="no-js "lang="en-US"> Flavius Martin - Medtech Alert
Thursday, July 31, 2025
Flavius Martin

Flavius Martin

About Flavius Martin

Flavius Martin is the Executive Vice President of Research at Gilead, overseeing the company’s innovative research and preclinical programs across all therapeutic areas. His organization is responsible for internal discovery research and for identifying important external opportunities for Gilead.

Flavius joined Gilead in 2021, after nearly 20 years in the biopharmaceutical industry. Immediately prior to Gilead, he served as Vice President, Research Biology at Amgen, leading Oncology, Inflammation and Cardiometabolic Research. He was also the site head for Amgen South San Francisco. Prior to Amgen, he worked as a scientist and leader at Genentech.

Flavius received his MD degree from the University of Medicine and Pharmacy Timisoara, Romania. He completed his postdoctoral studies at the University of Alabama at Birmingham in the Division of Developmental and Clinical Immunology.

Related Story

Gilead Sciences Completes Acquisition of MiroBio

September 22 2022

GMiroBioilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to […]

Gilead Sciences to Acquire MiroBio

August 5 2022

Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring […]

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

May 3 2022

Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance […]